ST6GALNAC1 Antibody

What is ST6GALNAC1 and what biological functions does it serve?

ST6GALNAC1 (ST6 N-Acetylgalactosaminide Alpha-2,6-Sialyltransferase 1) is a glycosyltransferase that catalyzes the synthesis of sialyl-Tn (sTn) antigen, which is critical for cell mobility. This enzyme functions by adding sialic acid to O-linked GalNAc residues, thereby promoting the formation of tumor-associated sTn O-glycans . ST6GALNAC1 has been found to be overexpressed in multiple cancer types, including gastric, breast, prostate, and colorectal cancers . In the context of cancer biology, ST6GALNAC1 plays a crucial role in enhancing cancer stem cell properties and contributing to tumor progression through modification of cell surface glycans .

What are the recommended applications for ST6GALNAC1 antibody?

ST6GALNAC1 antibody (such as the 15363-1-AP clone) has been validated for several experimental applications, with specific recommended dilutions for optimal results:

The antibody has been tested and confirmed to show reactivity with human, mouse, and rat samples . For IHC applications, it's important to note that antigen retrieval conditions significantly impact staining quality, with TE buffer pH 9.0 generally providing optimal results (alternatively, citrate buffer pH 6.0 can be used) .

How should ST6GALNAC1 antibody be stored and handled for optimal performance?

For maximum stability and activity, the ST6GALNAC1 antibody should be stored at -20°C in its provided buffer (typically PBS with 0.02% sodium azide and 50% glycerol at pH 7.3) . Under these conditions, the antibody remains stable for approximately one year after shipment. Importantly, aliquoting is generally unnecessary for -20°C storage, which simplifies laboratory handling protocols. Smaller size formats (20μl) typically contain 0.1% BSA as a stabilizing agent . When working with the antibody, avoid repeated freeze-thaw cycles and exposure to strong light sources, as these conditions can compromise antibody performance and specificity.

How can I validate the specificity of ST6GALNAC1 antibody in my experimental system?

Validating antibody specificity is crucial for obtaining reliable research results. For ST6GALNAC1 antibody, a comprehensive validation approach should include:

• Positive and negative controls: Use tissues known to express ST6GALNAC1 (colon, small intestine) as positive controls . Consider using knockout/knockdown systems as negative controls.

• Multiple detection methods: Compare results across different techniques (WB, IHC, IF) when possible.

• siRNA knockdown verification: Perform siRNA-mediated knockdown of ST6GALNAC1 and confirm reduced signal with the antibody. Studies have demonstrated significant reduction in ST6GALNAC1 expression using specific siRNAs (siRNA1 and siRNA3) .

• Recombinant expression systems: Overexpress ST6GALNAC1 in appropriate cell lines and confirm increased antibody signal.

• Molecular weight confirmation: Verify that the detected band appears at the expected molecular weight (66-69 kDa for ST6GALNAC1) .

This multi-faceted approach helps ensure that the observed signals genuinely represent ST6GALNAC1 rather than non-specific binding.

What are the critical controls needed when studying ST6GALNAC1 in cancer stem cell research?

When investigating ST6GALNAC1's role in cancer stem cells (CSCs), several key controls are essential:

• Sphere formation assays: Compare sphere-forming ability between ST6GALNAC1-overexpressing, wild-type, and knockdown cells. Research has shown that ST6GALNAC1 overexpression enhances sphere formation, while knockdown significantly reduces it .

• Expression markers: Monitor established CSC markers (ALDH1, SOX2) alongside ST6GALNAC1 manipulation. Studies demonstrate that ST6GALNAC1 knockdown decreases protein expression levels of these stemness markers .

• Chemoresistance testing: Assess sensitivity to chemotherapeutic agents (e.g., 5-FU) following ST6GALNAC1 modulation. ST6GALNAC1 knockdown has been shown to significantly increase sensitivity to 5-FU .

• In vivo tumorigenicity: Perform limiting dilution xenograft studies to quantify CSC frequency. Research indicates that ST6GALNAC1-knockdown cells form significantly smaller tumors than control cells, suggesting decreased CSC properties .

• STn antigen expression: Confirm changes in STn antigen expression correspond with ST6GALNAC1 manipulation, as this glycan modification is directly produced by the enzyme's activity .

How does ST6GALNAC1 contribute to the tumor microenvironment, particularly in relation to macrophage interactions?

ST6GALNAC1 plays a sophisticated role in tumor-macrophage crosstalk within the tumor microenvironment. Recent research reveals a complex regulatory mechanism:

• Macrophage-induced expression: M2-like macrophages (associated with tumor-promoting functions) induce ST6GALNAC1 expression in colon cancer cells .

• Cytokine mediation: This induction occurs primarily through IL-13 and CCL17 signaling. Blocking antibody experiments have confirmed these cytokines as key mediators .

• STAT6 signaling pathway: IL-13 activates ST6GALNAC1 transcription through phosphorylation of STAT6, which directly binds to the ST6GALNAC1 gene promoter. Chromatin immunoprecipitation assays of human UC and CACC samples have confirmed this mechanism .

• Glycoform alterations: Increased ST6GALNAC1 expression results in the production of MUC1-sTn glycoform, which is associated with colonic inflammation and cancer progression .

• Inflammatory amplification: The resulting changes in cellular glycosylation may further modify immune cell recruitment and activity, creating a feed-forward loop that promotes tumor progression .

This intricate interplay represents a potential therapeutic target, as computational modeling has identified possible intervention points in this signaling network .

What is the relationship between ST6GALNAC1, STn antigen, and cancer stem cell maintenance?

ST6GALNAC1 plays a crucial role in cancer stem cell (CSC) maintenance through its enzymatic activity and downstream signaling effects:

• STn antigen production: ST6GALNAC1 catalyzes the addition of sialic acid to O-linked GalNAc residues, creating the tumor-associated sialyl-Tn (STn) antigen .

• CD44 modification: Research has identified CD44, a well-established CSC marker, as a carrier protein for STn antigen. Immunoprecipitation studies followed by mass spectrometry analysis confirmed that CD44 is specifically modified with STn antigen in ST6GALNAC1-overexpressing cells .

• Akt pathway activation: ST6GALNAC1 overexpression activates the Akt signaling pathway, a key regulator of cell survival and proliferation. This activation appears to be mediated through cooperation with galectin-3, as galectin-3 knockdown cancels this effect .

• CSC phenotype enhancement: Experimental evidence demonstrates that ST6GALNAC1 overexpression increases sphere-forming ability and chemoresistance, two hallmark properties of CSCs. Conversely, ST6GALNAC1 knockdown significantly reduces these properties .

• In vivo tumor initiation: ST6GALNAC1 knockdown cells form significantly smaller tumors in xenograft models, indicating reduced CSC frequency. Using Extreme Limiting Dilution Analysis (ELDA), researchers have quantified that ST6GALNAC1 knockdown significantly reduces the CSC ratio in colorectal cancer cell populations .

These findings collectively suggest that ST6GALNAC1 maintains CSC properties through glycosylation of key cell surface proteins and subsequent activation of pro-survival signaling pathways.

What are the optimal immunohistochemistry protocols for detecting ST6GALNAC1 in different tissue types?

Successful immunohistochemical detection of ST6GALNAC1 requires careful optimization of several parameters:

• Tissue preparation: Use 4-6 μm sections of formalin-fixed, paraffin-embedded tissues. Fresh frozen sections may also be used but typically yield different staining patterns.

• Antigen retrieval: For most tissue types, heat-induced epitope retrieval with TE buffer (pH 9.0) provides optimal results. For tissues with high proteolytic activity, alternative antigen retrieval using citrate buffer (pH 6.0) may be considered .

• Blocking and antibody incubation:

  • Block with 3-5% normal serum from the same species as the secondary antibody

  • Use primary antibody at 1:50-1:500 dilution (optimal dilution is tissue-dependent)

  • Incubate at 4°C overnight for maximum sensitivity or 1-2 hours at room temperature

• Detection system: For maximum sensitivity, especially in tissues with low ST6GALNAC1 expression, use polymer-based detection systems rather than standard ABC methods.

• Tissue-specific considerations:

  • Human skin tissue: Positive IHC staining has been well documented

  • Colon tissue: High background may occur; extended blocking steps (2-3 hours) may improve signal-to-noise ratio

  • Cancer tissues: Consider dual staining with macrophage markers to assess correlations between macrophage infiltration and ST6GALNAC1 expression

How can I effectively design experiments to study the relationship between ST6GALNAC1 and specific glycan structures?

Investigating ST6GALNAC1's relationship with glycan structures requires a multi-faceted experimental approach:

• Genetic manipulation strategies:

  • Use siRNA knockdown of ST6GALNAC1 (validated sequences available from published studies)

  • Generate stable overexpression cell lines using lentiviral or plasmid-based systems

  • Consider CRISPR/Cas9 for complete gene knockout studies

• Glycan detection methods:

  • Use anti-STn antibodies to directly detect the glycan product of ST6GALNAC1 activity

  • Employ lectin blotting with Sambucus nigra agglutinin (SNA) to detect α2,6-linked sialic acids

  • Consider mass spectrometry for comprehensive glycan profiling

• Carrier protein identification:

  • Perform immunoprecipitation with anti-STn antibodies followed by silver staining and mass spectrometry analysis

  • Confirm findings with Western blotting using antibodies against candidate carrier proteins (CD44 has been identified as a key carrier)

• Functional assessment:

  • Evaluate biological consequences of altered glycosylation through sphere formation assays

  • Assess drug resistance profiles

  • Measure cell migration and invasion capabilities

• Signaling pathway analysis:

  • Investigate activation of downstream pathways (Akt pathway has been implicated)

  • Use pathway inhibitors to determine causal relationships

  • Consider phospho-specific antibodies to detect activated signaling molecules

How can I address non-specific binding issues when using ST6GALNAC1 antibody?

Non-specific binding can significantly compromise experimental results. To minimize this issue:

• Antibody validation: Confirm your antibody recognizes the correct target. Unlike the issues reported with ST6GAL1 antibodies , ensure your ST6GALNAC1 antibody has been properly validated against positive and negative controls.

• Blocking optimization:

  • For Western blotting: Use 5% non-fat dry milk or BSA in TBST, extending blocking time to 2 hours at room temperature

  • For IHC/ICC: Consider using species-specific serum matching your secondary antibody, or commercial blocking solutions

• Antibody dilution: Titrate your antibody carefully. While recommended ranges are 1:500-1:1000 for WB and 1:50-1:500 for IHC , optimal dilutions may vary by application and tissue type.

• Washing procedures: Increase wash steps duration and number (minimum 3×10 minutes with TBST or PBS-T) to remove unbound antibody.

• Secondary antibody considerations: Use highly cross-adsorbed secondary antibodies to minimize species cross-reactivity.

• Positive and negative controls: Always include appropriate controls:

  • Tissue-specific positive controls (colon tissue shows consistent expression)

  • Primary antibody omission controls

  • Isotype controls

  • Knockdown/knockout samples when available

How should contradictory results between ST6GALNAC1 expression and functional outcomes be interpreted?

Researchers occasionally encounter contradictory results when studying ST6GALNAC1. These discrepancies may arise from several factors:

• Context-dependent functions: ST6GALNAC1's effects may vary depending on:

  • Cell type (epithelial vs. mesenchymal)

  • Disease stage (early vs. late cancer)

  • Tumor microenvironment (inflammatory vs. immunosuppressive)

• Technical considerations:

  • Antibody specificity issues (similar to those documented with ST6GAL1)

  • Detection of protein vs. enzymatic activity

  • Glycan redundancy (other enzymes may compensate for ST6GALNAC1 loss)

• Experimental approach reconciliation:

  • Combine multiple techniques (WB, IHC, qPCR) to confirm expression patterns

  • Use both gain-of-function and loss-of-function approaches

  • Consider temporal aspects (acute vs. chronic manipulation)

• Analysis framework:

  • When encountering contradictory results, systematically document differences in experimental conditions

  • Consider that ST6GALNAC1 may form part of a complex regulatory network rather than functioning in isolation

  • Examine carrier protein expression levels, as ST6GALNAC1's effects depend on available substrates

• Collaborative validation: When possible, validate findings across different laboratories using standardized protocols to identify sources of variability.

What are promising therapeutic strategies targeting ST6GALNAC1 in cancer?

Given ST6GALNAC1's role in cancer progression and stem cell maintenance, several therapeutic approaches show promise:

• Direct enzyme inhibition:

  • Development of small molecule inhibitors targeting ST6GALNAC1's catalytic domain

  • Substrate analogs that compete with natural substrates

  • Allosteric modulators affecting enzyme activity

• Upstream signaling intervention:

  • IL-13 pathway inhibitors, as IL-13 activates ST6GALNAC1 transcription via STAT6

  • CCL17 neutralizing antibodies to disrupt macrophage-tumor cell communication

  • Targeting M2 macrophage polarization to reduce ST6GALNAC1 induction

• Downstream pathway targeting:

  • Akt pathway inhibitors to counteract ST6GALNAC1-mediated activation

  • Galectin-3 inhibitors, as galectin-3 cooperates with ST6GALNAC1 in activating Akt

• Immunotherapeutic approaches:

  • Development of CAR-T cells targeting STn antigen-bearing cells

  • Vaccines against STn-modified proteins to generate anti-tumor immune responses

  • Immune checkpoint inhibitors combined with ST6GALNAC1 targeting

• Combinatorial strategies:

  • Sensitization to conventional chemotherapy through ST6GALNAC1 inhibition

  • Targeting cancer stem cell populations with ST6GALNAC1 inhibitors followed by conventional therapies

  • Modulating the tumor microenvironment while inhibiting ST6GALNAC1

How can computational modeling enhance our understanding of ST6GALNAC1's role in disease progression?

Computational approaches offer powerful tools for elucidating ST6GALNAC1's complex roles:

• Signaling pathway modeling:

  • Computational models can integrate known interactions involving ST6GALNAC1, as demonstrated in studies of macrophage-tumor cell crosstalk

  • Sensitivity analysis can identify key nodes within ST6GALNAC1-related pathways

  • Predict effects of potential therapeutic interventions before experimental validation

• Structure-based drug design:

  • Molecular docking studies to screen potential ST6GALNAC1 inhibitors

  • Molecular dynamics simulations to understand enzyme-substrate interactions

  • Computer-aided design of molecules targeting ST6GALNAC1's catalytic site

• Multi-scale modeling approaches:

  • Integrate cellular, tissue, and organism-level data to predict systemic effects of ST6GALNAC1 modulation

  • Agent-based models to simulate tumor-immune interactions influenced by altered glycosylation

  • Population-level models to predict therapeutic outcomes in heterogeneous patient populations

• Machine learning applications:

  • Analyze large datasets to identify novel correlations between ST6GALNAC1 expression and clinical outcomes

  • Predict patient subgroups most likely to benefit from ST6GALNAC1-targeted therapies

  • Discover unexpected relationships between ST6GALNAC1 and other biological processes

• Integration with experimental data:

  • Use computational models to guide experimental design

  • Iteratively refine models with new experimental findings

  • Develop predictive biomarkers for personalized medicine approaches